Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Macrogenics Inc (NASDAQ: MGNX) closed at $2.32 in the last session, up 1.75% from day before closing price of $2.28. In other words, the price has increased by $1.75 from its previous closing price. On the day, 0.74 million shares were traded.
Ratios:
We take a closer look at MGNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.69 and its Current Ratio is at 3.75. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.24.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 15 ’25 when Smith Beth Ann sold 423 shares for $2.56 per share. The transaction valued at 1,083 led to the insider holds 9,532 shares of the business.
Peters Jeffrey Stuart sold 51,395 shares of MGNX for $799,148 on Apr 04 ’24. The Senior VP and General Counsel now owns 0 shares after completing the transaction at $15.55 per share. On Mar 06 ’24, another insider, Peters Jeffrey Stuart, who serves as the Senior VP and General Counsel of the company, sold 19,625 shares for $21.50 each. As a result, the insider received 421,938 and left with 8,895 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.03 while its Price-to-Book (P/B) ratio in mrq is 1.21.
Stock Price History:
Over the past 52 weeks, MGNX has reached a high of $21.88, while it has fallen to a 52-week low of $2.26. The 50-Day Moving Average of the stock is -21.38%, while the 200-Day Moving Average is calculated to be -37.00%.
Shares Statistics:
A total of 62.76M shares are outstanding, with a floating share count of 57.70M. Insiders hold about 8.07% of the company’s shares, while institutions hold 84.47% stake in the company.
Earnings Estimates
As of right now, 3.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.58 and low estimates of -$1.1.
Analysts are recommending an EPS of between -$1.24 and -$1.79 for the fiscal current year, implying an average EPS of -$1.54. EPS for the following year is -$2.77, with 4.0 analysts recommending between -$2.4 and -$3.01.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $34.17M. It ranges from a high estimate of $58.6M to a low estimate of $7.7M. As of the current estimate, Macrogenics Inc’s year-ago sales were $10.72MFor the next quarter, 6 analysts are estimating revenue of $9.32M. There is a high estimate of $13.2M for the next quarter, whereas the lowest estimate is $6.6M.
A total of 7 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $189.2M, while the lowest revenue estimate was $133M, resulting in an average revenue estimate of $160.24M. In the same quarter a year ago, actual revenue was $58.75MBased on 7 analysts’ estimates, the company’s revenue will be $58.52M in the next fiscal year. The high estimate is $153.56M and the low estimate is $21.2M.
